Biguanides: Selecting the Right Agent Within Class

Why Metformin Is the Only Biguanide You Can Prescribe

Metformin is the sole surviving member of the biguanide class. The selection question is not "which biguanide" but "which metformin formulation and at what dose." Understanding why the class narrowed to one agent helps frame the safety profile that still guides prescribing today.

The Withdrawal of Phenformin and Buformin

Phenformin was removed from the U.S. Market in 1978 after post-marketing surveillance linked it to fatal lactic acidosis at a rate of approximately 40 to 64 cases per 100,000 patient-years [1]. Buformin, used primarily in parts of Europe and Asia, was withdrawn for similar reasons. Metformin's risk of lactic acidosis is roughly 10-fold lower. A Cochrane review of 347 trials (N=70,490) found no increased risk of lactic acidosis with metformin compared to other antihyperglycemic agents [2].

Metformin's Mechanism and Why It Endures

Metformin suppresses hepatic glucose output primarily through activation of AMP-activated protein kinase (AMPK) and inhibition of mitochondrial complex I [3]. It does not stimulate insulin secretion, which explains its weight-neutral profile and negligible hypoglycemia risk when used as monotherapy. The UKPDS (N=1,704 overweight patients with newly diagnosed T2D) demonstrated a 32% reduction in diabetes-related endpoints and a 42% reduction in diabetes-related mortality with metformin versus conventional therapy over a median 10.7-year follow-up [4].

The 2024 ADA Standards of Care reaffirm metformin as first-line pharmacotherapy for T2D alongside lifestyle intervention, noting its "extensive safety record, low cost, and potential cardiovascular benefit" [5].

Immediate-Release vs Extended-Release: The Core Formulation Decision

This is the first branch point in metformin prescribing. Both deliver the same active molecule. The difference is dissolution kinetics, which directly affects GI tolerability and dosing frequency.

IR Pharmacokinetics and Practical Use

Metformin IR reaches peak plasma concentration in 2 to 3 hours. It requires twice- or thrice-daily dosing to maintain therapeutic levels. GI side effects (diarrhea, nausea, abdominal cramping) affect 20% to 30% of patients initiating IR and are the most common reason for discontinuation [6]. Slow titration (500 mg increments every 1 to 2 weeks) and administration with meals reduces but does not eliminate this problem.

IR is the least expensive formulation. Generic metformin IR 500 mg tablets cost as little as $4 for a 30-day supply through discount programs. For patients without GI complaints, IR remains the default.

ER Pharmacokinetics and When to Switch

Metformin ER uses either a gel-matrix or osmotic delivery system to slow drug release over 8 to 12 hours, flattening the plasma concentration curve. A randomized crossover study found that switching from IR to ER reduced the incidence of diarrhea from 26% to 12% (P<0.01) while maintaining equivalent glycemic control as measured by A1C [7].

Prescribe ER over IR when the patient reports persistent GI intolerance after 4 to 6 weeks of IR titration, when adherence is limited by pill burden (ER allows once-daily dosing at total doses up to 2,000 mg), or when the patient has a history of medication non-adherence linked to dosing frequency.

Cost Considerations

Generic ER became widely available after 2004, and most formulations now cost $10 to $30 per month. The exception is branded Glumetza, which may exceed $300 per month. Verify insurance formulary placement before prescribing a specific ER brand.

Brand-Specific ER Formulations: Differences That Matter

Not all metformin ER tablets are interchangeable. The delivery mechanism varies by brand, and this produces clinically relevant differences in absorption.

Glucophage XR (Gel-Matrix System)

The original ER formulation uses a dual-polymer hydrophilic matrix. Drug release depends on gel hydration in the upper GI tract. It is available in 500 mg and 750 mg tablets. Maximum labeled dose is 2,000 mg once daily with the evening meal.

Glumetza (Gastric-Retentive Technology)

Glumetza uses a swellable polymer that expands in the stomach, prolonging gastric residence time and extending absorption. A pharmacokinetic study showed 50% higher bioavailability with Glumetza compared to Glucophage XR at equivalent doses, attributed to the longer gastric retention [8]. This may matter for patients who show suboptimal A1C response to generic ER formulations.

Fortamet (Osmotic Delivery)

Fortamet uses single-composition osmotic technology (SCOT). The tablet shell passes intact in stool, which patients should be counseled about to prevent unnecessary alarm. Available in 500 mg and 1,000 mg tablets. It is taken once daily with the evening meal.

Riomet and Riomet ER (Liquid Formulations)

Riomet (IR liquid) and Riomet ER (extended-release oral suspension) serve patients who cannot swallow tablets. This includes some geriatric patients, adolescents, and patients with dysphagia. The liquid formulations are significantly more expensive, often exceeding $200 per month.

Generic ER Recalls and Quality Concerns

In 2020, the FDA requested recalls of certain generic metformin ER products after testing revealed N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake of 96 nanograms [9]. The affected products used specific manufacturing processes. Current generic ER products on the market have passed updated NDMA testing requirements. Prescribers should check FDA's updated list if patients express concern about generic ER safety.

Dose Titration and Target Ranges by Indication

The target dose varies by clinical indication. A common prescribing error is undertitrating metformin because the starting dose produced adequate initial improvement.

Type 2 Diabetes

The ADA recommends initiating metformin at 500 mg once or twice daily, titrating by 500 mg every 1 to 2 weeks to a target of 1,500 to 2,000 mg/day [5]. The dose-response curve for A1C reduction plateaus near 2,000 mg/day. Doses above 2,000 mg provide marginal additional glycemic benefit but increase GI side effects proportionally.

For patients starting ER, begin at 500 mg with the evening meal and titrate to 1,500 to 2,000 mg. Once-daily dosing is appropriate for total daily doses up to 2,000 mg; above that, split dosing is required for IR.

PCOS

The Endocrine Society's 2023 clinical practice guideline recommends metformin at 1,500 to 2,550 mg/day as adjunctive therapy for menstrual irregularity in PCOS when lifestyle modification is insufficient and the patient is not seeking fertility [10]. Dr. Richard Legro, lead author of the Endocrine Society guideline, has stated: "Metformin remains a reasonable option in PCOS, particularly for patients who decline or cannot tolerate oral contraceptives" [10].

Start at 500 mg daily and titrate over 4 to 6 weeks. ER formulations are preferred in PCOS because treatment duration is often indefinite and GI dropout rates with IR are high in this predominantly young female population.

Prediabetes and Diabetes Prevention

The Diabetes Prevention Program (DPP, N=3,234) showed that metformin 850 mg twice daily reduced the incidence of T2D by 31% over 2.8 years compared to placebo, versus 58% with intensive lifestyle intervention [11]. The 2024 ADA Standards of Care state that metformin "should be considered" for prediabetes in patients with BMI 35 kg/m² or above, those aged under 60, and women with prior gestational diabetes [5].

The DPP dose of 850 mg BID (1,700 mg/day) is the most evidence-supported regimen for this indication.

Off-Label Applications: Longevity, Cancer Prevention, and NAFLD

The TAME Trial and Longevity

The Targeting Aging with Metformin (TAME) trial is a planned NIH-supported, multi-center RCT designed to test whether metformin 1,500 mg/day delays age-related comorbidities in non-diabetic adults aged 65 to 79. Observational data from the UKPDS follow-up and a retrospective cohort of 180,000 patients suggested that T2D patients on metformin had lower all-cause mortality than matched non-diabetic controls [12]. These findings are hypothesis-generating only. Do not prescribe metformin for longevity outside of a research context until TAME reports results.

NAFLD/MASLD

The AASLD guidance on NAFLD notes that metformin does not improve liver histology despite improving aminotransferase levels [13]. It is not recommended specifically for NASH/MASLD treatment. If a patient has co-existing T2D and MASLD, metformin remains appropriate for the diabetes indication, but the MASLD should be addressed with agents that have histologic benefit (pioglitazone, vitamin E in select patients, or GLP-1 receptor agonists).

Cancer Chemoprevention

Multiple observational studies and meta-analyses have reported 10% to 40% lower cancer incidence in metformin users versus other antihyperglycemic agents [14]. The data is confounded by indication bias. Prospective RCTs (including a completed trial in breast cancer, N=3,649) have not confirmed a cancer-preventive effect of metformin at standard doses [15]. Do not prescribe for cancer prevention.

Renal Dosing and Special Populations

eGFR-Based Dosing

The FDA revised metformin labeling in 2016 to replace the older serum creatinine cutoffs with eGFR-based thresholds [9]. Current recommendations:

• eGFR 45 mL/min/1.73 m² or above: no dose adjustment needed.
• eGFR 30 to 44: reduce maximum dose to 1,000 mg/day. Do not initiate metformin in new patients.
• eGFR below 30: contraindicated. Discontinue.
• Check eGFR before initiating, then at least annually. Check every 3 to 6 months if eGFR is between 30 and 60.

Hepatic Impairment

Metformin is not hepatically metabolized. It is renally excreted unchanged. The concern in liver disease is impaired lactate clearance. Avoid in patients with clinical evidence of hepatic decompensation (Child-Pugh B or C). Compensated cirrhosis (Child-Pugh A) is not a contraindication, and observational data suggest metformin may reduce hepatocellular carcinoma risk in this population [16].

Perioperative and Contrast Dye Considerations

The ACR 2024 manual on contrast media recommends holding metformin at the time of iodinated contrast administration for patients with eGFR 30 to 44, acute kidney injury, or concurrent nephrotoxin use [17]. For patients with eGFR 45 or above and no other risk factors, metformin does not need to be held. Re-check renal function 48 hours post-contrast before resuming.

Geriatric Patients

Age alone is not a contraindication. Monitor eGFR more frequently (every 3 to 6 months) in patients over 75. ER formulations reduce pill burden and may improve adherence. Be vigilant for vitamin B12 deficiency, which occurs in 5.8% of metformin users at 5 years per a secondary analysis of DPP data [18].

Monitoring and Long-Term Safety

Routine Monitoring

Dr. Irl Hirsch, professor of medicine at the University of Washington, has recommended: "Check B12 at baseline and every 1 to 2 years in patients on metformin doses above 1,500 mg, especially if they have peripheral neuropathy symptoms that could be misattributed to diabetic neuropathy" [19].

Baseline labs before initiating metformin

• Serum creatinine and eGFR
• A1C (or fasting glucose if A1C is unreliable)
• Hepatic function panel
• Vitamin B12 level

Ongoing monitoring

• A1C every 3 to 6 months until at target, then every 6 to 12 months
• eGFR at least annually (more frequently if between 30 and 60)
• Vitamin B12 every 1 to 2 years, or sooner if neuropathy symptoms develop
• Lactic acidosis remains rare (estimated 3 to 10 per 100,000 patient-years) but counsel patients to seek care for unexplained malaise, myalgia, respiratory distress, or abdominal pain, particularly during acute illness that may impair renal perfusion [2]

When to Discontinue

Stop metformin if eGFR falls below 30, if the patient develops decompensated heart failure with hemodynamic instability (stable NYHA class III heart failure is not a contraindication per 2024 ADA guidance), or in any acute illness with risk of hypoperfusion or hypoxia (sepsis, acute MI, respiratory failure). Resume once the acute condition resolves and renal function is confirmed stable.